Alzheimer's biotech Cognition Therapeutics files for a $50 million IPO - (NASDAQ via NewsPoints Desk)

  • Cognition Therapeutics filed on Monday with the SEC to raise up to $50 million in an initial public offering, as reported in NASDAQ.

  • The company is developing small molecule therapies for age-related degenerative diseases and disorders of the central nervous system (CNS) and the retina, with an initial aim to leverage its expertise in the sigma-2 receptor.

  • Its lead program, CT1812, is a small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

  • CT1812 is currently in enrolling patients in a Phase II trial in patients with mild-to-moderate Alzheimer's disease.  

To read more NewsPoints articles, click here.